NDAORALTABLET
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LIPTRUZET (atorvastatin calcium; ezetimibe) by Merck & Co. is selective, competitive inhibitor of hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-‑methylglutaryl-coenzyme a to mevalonate, a precursor of sterols, including cholesterol. Approved for elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b) and 8 more indications. First approved in 2013.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPTRUZET is a fixed-dose oral combination tablet containing atorvastatin calcium and ezetimibe, approved by the FDA in May 2013. It treats elevated cholesterol and triglycerides by dual mechanism: atorvastatin inhibits HMG-CoA reductase to reduce liver cholesterol synthesis, while ezetimibe blocks intestinal cholesterol absorption. The combination is indicated for patients with primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations and established team structures focused on market maintenance.
Mechanism of Action
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-‑methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting…
Worked on LIPTRUZET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.